Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 15/20 | 0.60 |
| ▸ | CA1 | P00915 | 15/20 | 0.60 |
| ▸ | CA2 | P00918 | 15/20 | 0.60 |
| ▸ | CA9 | Q16790 | 15/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5739204 | 1.00 | CA12 (0.60) | CA12CA1CA2CA9CA14 | |
| Bromide SCHEMBL5743154 | 1.00 | CA12 (0.60) | CA12CA1CA2CA9CA14 | |
| Bromide SCHEMBL10716847 | 0.99 | CA12 (0.57) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7623838 | 0.99 | CA12 (0.61) | CA12CA1CA2CA9CA14 | |
| Bromide SCHEMBL10714182 | 0.87 | CA12 (0.60) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL5741360 | 0.85 | LMNA (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7151935 | 0.85 | CA12 (0.67) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13163929 | 0.85 | CA12 (0.67) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13480225 | 0.85 | CA12 (0.67) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7151688 | 0.85 | CA12 (0.67) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050036948-A1 | Radiolabeled annexins | NEORX CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1486509-A2 | Radiolabeled annexin-galactose cluster conjugates | NEORX CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-0799050-B1 | RADIOLABELED ANNEXIN-GALACTOSE CLUSTER CONJUGATES | NEORX CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-1426062-A2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0918547-B1 | RADIOLABELED ANNEXINS | NEORX CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6172045-B1 | COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-6171577-B1 | ACCESSIBLE SULFHYDRYL GROUP; AND HEXOSE MOIETY RECOGNIZED BY A MAMMALIAN LIVER RECEPTOR, WHEREIN THE HEXOSE MOIETY IS CONJUGATED TO THE ANNEXIN. | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-5985826-A | Methods of using hepatic-directed compounds in pretargeting strategies | NEORX CORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5968477-A | IMAGING AGENTS WITH SULFHYDRYL GROUPS AND HEXOSE GROUPS | NEORX CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0918547-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5886143-A | Hepatic-directed compounds and reagents for preparation thereof | NEORX CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | ADRA2A 1893/4885ADRA2B 1412/4885CA12 1214/4885 |
| US-20050036948-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | ADRA2A 1893/4885ADRA2B 1412/4885CA12 1214/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | ADRA2A 1893/4885ADRA2B 1412/4885CA12 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.